Swiss - Delayed Quote CHF

Galderma Group N (GALD.SW)

Compare
107.68
-0.82
(-0.76%)
As of 12:23:24 PM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GALD.SW

Recent News: GALD.SW

View More
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
Business Wire 30 days ago
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
Business Wire last month
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Business Wire last month
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation
Business Wire 2 months ago
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends
Business Wire 2 months ago
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance
Business Wire 2 months ago
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
Business Wire 2 months ago
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
Business Wire 3 months ago
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
Business Wire 4 months ago
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
Business Wire 5 months ago
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
Business Wire 5 months ago
View More

Related Tickers

SDZ.SW Sandoz Group AG
39.01
-0.41%
 
SFZN.SW Siegfried Holding AG
983.00
-0.51%
 
4523.T Eisai Co., Ltd.
4,259.00
-2.65%
 
EOLS Evolus, Inc.
10.00
-2.06%
 
SDZNY Sandoz Group AG
42.65
-0.16%
 
ALKS Alkermes plc
28.08
-1.20%
 
SOBI.ST Swedish Orphan Biovitrum AB (publ)
322.80
+3.07%
 
MRK.DE Merck KGaA
140.75
-1.26%
 
TAK Takeda Pharmaceutical Company Limited
12.95
-2.19%
 
APH.L Alliance Pharma plc
61.15
+0.08%